维生素D-24-羟化酶与甲状腺癌的相关性研究进展  

Advances in the study of the correlation between vitamin D-24-hydroxylase and thyroid carcinoma

作　　者：陈施静 傅菁岚 邓媛媛 张颖[1] 刘慧霞[1] CHEN Shijing;FU Jinglan;DENG Yuanyuan;ZHANG Ying;LIU Huixia(Department of Geriatric Endocrinology,Xiangya Hospital,Central South University,Changsha 410031,China)

机构地区：[1]中南大学湘雅医院老年医学内分泌科,长沙410031

出　　处：《基础医学与临床》2023年第3期490-494,共5页Basic and Clinical Medicine

基　　金：国家自然科学基金(81873672)。

摘　　要：甲状腺癌(TC)是内分泌系统最常见的恶性肿瘤,维生素D缺乏患者TC患病风险增加。维生素D-24-羟化酶(CYP24A1)是活性维生素D的主要灭活酶,通过灭活1,25-二羟基维生素D_(3),抑制维生素D抗增殖效应,促进TC的发生发展。Thyroid carcinoma(TC) is the most common malignant tumor of endocrine system.Patients with vitamin D deficiency have an increased risk of TC.Vitamin D-24-hydroxylase(CYP24A1) is main inactivating enzyme of active vitamin D which may inhibit the antiproliferative effect of vitamin D and promote the development of TC by inactivating 1,25-dihydroxyvitamin D_(3).

关 键 词：维生素D-24-羟化酶 甲状腺癌 维生素D 

分 类 号：R34[医药卫生—基础医学]